arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cellectar Biosciences, Inc.

CLRB
$1.15 ▼ -0.07 (-5.74%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cellectar Biosciences, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $14.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -19.0% ↗
FCF / Share $-0.49 ↗
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.65M
↑ +14.4% —
FCF / Share Free cash flow per share
$-0.49
↑ +57.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Cash Quality ↑
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 24 years · 75 quarters